Long term (current) use of aromatase inhibitors

This code indicates a patient is currently receiving long-term therapy with an aromatase inhibitor medication. These drugs are primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women by blocking the production of estrogen. It signifies ongoing management rather than a short-term course.

Assign this code when documenting a patient's current and sustained use of an aromatase inhibitor, such as anastrozole, letrozole, or exemestane, for conditions like breast cancer. This is typically used for adjuvant or neoadjuvant therapy extending over a significant period. It should be reported as a secondary diagnosis to provide context for the patient's overall medical management.

• Always sequence this code after the definitive diagnosis for which the aromatase inhibitor is being used (e.g., breast cancer).
• Do not use this code for short-term or acute medication use; it specifically denotes long-term therapy.
• Verify the patient is actively taking the medication at the time of the encounter to ensure current use.